Aspen Neuroscience will Present at the Annual iPSC-Derived Cell Therapies Summit

We are looking forward to presenting this week at the annual iPSC-Derived Cell Therapies Summit in Boston. Xiaokui Zhang, PhD, Aspen’s Chief Scientific officer will serve as a panel member on Tuesday, December 6th at 8:30 a.m. during “Industry Leaders’ Fireside Chat: Taking a Look at the Current Learnings from iPSC-Derived Cell Therapies & Determining Future Outlook & Developments,” where she will reflect on current learnings from therapeutics development to drive focus and motivation while highlighting demands of the future. This panel will also discuss validating iPSCs as a starting material for immune-oncology and regenerative medicine therapies to drive further investment and efforts in the space. 

On Tuesday at 4:30 p.m., Thorsten Gorba, PhD, Vice President, Manufacturing will present during the seminar, “Establishing Effective Potency Assays to Test Therapy Efficacy,” where he will discuss markers and characteristics that can help to predict clinical effectiveness to measure in assays, establishing potency assays to assess the actions and functions of iPSC products to safeguard cell activity, and certifying that iPSC products have potency levels of original cells through assays. Stop by and say hello! 

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.